Who is sponsoring NCT04612972?

NCT04612972 is sponsored by Universidad Peruana Cayetano Heredia.

What drugs are being tested in NCT04612972?

Interventions in NCT04612972: Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo.

Is NCT04612972 still recruiting?

NCT04612972 is currently completed. Last updated 1 May 2023.

Last reviewed 2023-05-01 · How we verify

NCT04612972: Covid-Peru

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru

Completed Phase 3 Last updated 1 May 2023

What this trial tests

Phase 3 trial testing Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo in COVID-19 in 12,000 participants. Completed in 3 April 2023.

Timeline

9 September 2020

Primary endpoint
19 February 2021

3 April 2023

Quick facts

Lead sponsor	Universidad Peruana Cayetano Heredia
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	12,000
Start date	9 September 2020
Primary completion	19 February 2021
Estimated completion	3 April 2023
Sites	1 location across Peru

Drugs / interventions tested

Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Universidad Peruana Cayetano Heredia — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Viral targets for vaccines against COVID-19.
Dai L, Gao GF. · · 2021 · cited 836× · PMID 33340022 · DOI 10.1038/s41577-020-00480-0
COVID-19 vaccines: rapid development, implications, challenges and future prospects.
Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. · · 2021 · cited 240× · PMID 33677814 · DOI 10.1007/s13577-021-00512-4
Efficacy and safety of COVID-19 vaccines.
Graña C, Ghosn L, Evrenoglou T, Jarde A, et al · · 2022 · cited 227× · PMID 36473651 · DOI 10.1002/14651858.cd015477
Wuhan to World: The COVID-19 Pandemic.
Kumar A, Singh R, Kaur J, Pandey S, et al · · 2021 · cited 109× · PMID 33859951 · DOI 10.3389/fcimb.2021.596201
SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review.
Fathizadeh H, Afshar S, Masoudi MR, Gholizadeh P, et al · · 2021 · cited 97× · PMID 34403674 · DOI 10.1016/j.ijbiomac.2021.08.076
Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines.
Zhou W, Wang W. · · 2021 · cited 97× · PMID 34108440 · DOI 10.1038/s41392-021-00644-x
An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.
García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, et al · · 2021 · cited 90× · PMID 33925526 · DOI 10.3390/vaccines9050433
COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials.
Yan ZP, Yang M, Lai CL. · · 2021 · cited 89× · PMID 33923054 · DOI 10.3390/ph14050406

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Universidad Peruana Cayetano Heredia trials

Trials by the same sponsor.

NCT06367361 — One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis · Phase 2 · not yet recruiting
NCT06989502 — Implementation of the COmmunity HEalth System InnovatiON Project in Low- and Middle- Income Countries · NA · not yet recruiting
NCT06565507 — Oxfendazole in Mild Parenchymal Brain Cysticercosis · Phase 2, PHASE3 · not yet recruiting
NCT05981378 — Genomic Approaches to Dissect Human Host-pathogen Interactions in the Amazonian Rainforest · not yet recruiting
NCT06500013 — WhatsApp Intervention to Assess the Effect of Messages in Adherence to Antiretrovirals in Young People With HIV in Peru · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04612972 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidad Peruana Cayetano Heredia
Last refreshed: 1 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04612972.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing